Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
“Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study Publisher Pubmed



Salarvand F1 ; Fatehi Z1 ; Shahali M1 ; Balighi K1 ; Ghiasi M1 ; Abedini R1 ; Mahmoudi H1 ; Tavakolpour S1 ; Chamsdavatchi C1 ; Daneshpazhooh M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Dermatologic Therapy Published:2019


Abstract

[No abstract available]
Related Docs
View other Related Docs
1. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)
2. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)
3. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (18)
Hamid Reza Mahmoodi (13)
Other Related Docs
4. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)
5. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)
6. Autoimmune Blistering Diseases Treated With Glucocorticoids: An International Study of Steroid-Induced Myopathy, Journal of the European Academy of Dermatology and Venereology (2025)
7. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)
8. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)
9. Unexpected Worsening of Pemphigus Vulgaris After Rituximab: A Report of Three Cases, International Immunopharmacology (2019)
10. Prevalence of Fungal Infections in Pemphigus Patients: A Systematic Review and Meta-Analysis, Mycoses (2024)
11. Pulmonary Nocardiosis in Pemphigus Vulgaris Patients From Tehran, Iran, Infectious Disorders - Drug Targets (2021)
12. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
13. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)
14. Diagnosis and Management of Pemphigus: Recommendations of an International Panel of Experts, Journal of the American Academy of Dermatology (2020)
15. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)
16. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)
17. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)
18. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)
19. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)